Clinical Trials Directory

We are doing this study to find out if an investigational drug called teclistamab (the study drug) is a safe and effective option for people who have multiple myeloma and have achieved at least a partial response to standard therapy. We want to know how well it works on its own and in combination with a standard drug called lenalidomide.

This study will last about two to a little over two years from the day you sign up until your last checkup. If the doctors decide you are a good fit after the first tests, you will have surgery to place the ARCIM System inside your body. After the surgery, you will have many checkups over the next two years so the study team can see how well the treatment is working for you. During these visits, the team will adjust the device to make sure it works well for your daily life. You will also answer questions and take part in health checkups during clinic visits. Some visits will be done by email or phone. Altogether, you will spend about fifteen days in person at the clinic during the whole study. The study team will be there to help and guide you at every step.

We are doing this study to learn more about how brain cell activity guides memory and navigation.

In this study, people are followed while they receive their regular cancer treatment with ADC medicines that their doctor chooses. The study does not give the medicines. It only watches how people do during their treatment. People can join before starting their first ADC or before starting their second ADC. The study follows them through each ADC treatment and then continues to check on them for two years after the second ADC. During treatment, people will answer questions about how they feel, the medicines they take, and any side effects. They will also fill out questionnaires about symptoms every other cycle. They will give small blood samples at certain times. If a biopsy is already being done as part of their normal care, extra tissue may be collected for research, but this is optional.

The Endometrial Cancer Molecularly Targeted Therapy Consortium is a multi-institutional alliance that is developing a cancer data and tissue repository. The information in this repository will be used to better understand tumor alterations and cancer biomarkers that can help us develop new therapies and potentially improve survival outcomes for women with endometrial cancer.

We are doing this study to keep tabs on the performance of a medical device called TVT Exact. This device is used to help control stress urinary incontinence. We want to know how well this device works long-term in Duke patients who elected to use it.